China Medical System Holdings Limited (CMS) has announced the signing of an exclusive commercialisation and supply agreement with Pharmacosmos A/S for two intravenous (IV) iron therapies, ferric derisomaltose (Monofer) and iron dextran (Cosmofer) in mainland China.
Under the agreement, CMS, through its wholly owned subsidiary, gains exclusive rights to commercialise the products in mainland China (excluding Hong Kong, Macau, and Taiwan), while Pharmacosmos will continue to manufacture and supply them. The partnership will run for 15 years, with the option for extension upon mutual agreement.
Both IV iron therapies are originator products already approved in China and included in the National Reimbursement Drug List (NRDL). Monofer is China’s first third-generation IV iron therapy, featuring a stable matrix-like nanoparticle structure that enables controlled iron release, improved safety, and the ability to deliver high-dose iron in a single infusion.
Cosmofer, meanwhile, is currently the only IV iron therapy listed in China’s Class A reimbursement category and the National Essential Medicines List. It has an established clinical track record with strong evidence supporting its safety and efficacy.
Together, the two products will create a comprehensive IV iron portfolio covering multiple clinical settings and patient needs, offering flexible treatment options for iron deficiency and iron deficiency anaemia.
Iron deficiency and iron deficiency anaemia affect patients across multiple specialties, including gastroenterology, cardiology, nephrology, obstetrics and gynaecology, and orthopaedics—areas where CMS already has strong clinical and academic networks.
The addition of these therapies is expected to create synergies with CMS’s existing portfolio, leveraging its established expert resources and academic promotion capabilities to enhance its competitive position in the anaemia treatment market.
Monofer offers key advantages over earlier IV iron formulations, including reduced infusion frequency, faster haemoglobin improvement, and lower risks of hypersensitivity reactions and hypophosphatemia. Its ability to deliver high-dose iron in a single session improves convenience for both patients and healthcare providers.
With this partnership, CMS aims to expand access to advanced IV iron therapies in China, supporting more efficient, safe, and patient-centric management of iron deficiency conditions.
The agreement is expected to contribute positively to CMS’s long-term growth while addressing a significant unmet need in anaemia care across the Chinese healthcare system.
